In the current study, an NGS panel targeting exons 18, 19, 20, and 21 of EGFR, and exons 2 and 3 of KRAS was used to compare the mutation status of ctDNA and paired tumor tissue DNA (tDNA). This evidence concerns the gene EGFR and neoplasm.